Close
Smartlab Europe
Inizio Ignite

Sun Pharma rolls out first ready to administer anti cancer drug in six European countries

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

AstraZeneca Breztri Reports Positive Phase III Trial Results

Results from the Phase III KALOS and LOGOS trials...

Sustainable Chemical Processes in Drug Manufacturing

Implementing green chemistry principles and sustainable chemical engineering in drug production is essential for reducing environmental impact and improving resource efficiency.

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...
- Advertisement -
Smart Lab Europe

Sun Pharma, India’s largest drug company has rolled out InfuSMART the first ever ready to administer version of anti cancer drug gemcitabine in six countries of Europe including Netherlands, UK, Spain, Germany, Italy and France.

 The company stated that InfuSMART will play an increasing role due to its efficiency in parameters of improved safety, convenience, saving time and providing differentiating solutions .

The product would be available in a bag. The company has received regulatory approval to sell gemcitabine InfuSMART in eight key stock keeping units. Gemcitabine is used in treating ovarian, lung, breast, and pancreatic cancer.

The company is working on its strategy to build “meaningful and differentiating presence in the global oncology therapy market”. The company has been building its efforts to build global branded products business and is focusing on areas where significant need gaps exist.

14 million new cases of cancer were detected in 2012, with 8 million deaths as per data from WHO. It is expected that cancer cases are expected to rise by over 70 per cent in the next two decades.

 

Smart Lab Europe

Latest stories

Related stories

AstraZeneca Breztri Reports Positive Phase III Trial Results

Results from the Phase III KALOS and LOGOS trials...

Sustainable Chemical Processes in Drug Manufacturing

Implementing green chemistry principles and sustainable chemical engineering in drug production is essential for reducing environmental impact and improving resource efficiency.

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...

Excipients Innovation Transforming Drug Delivery Performance

Analysis of the evolving role of functional excipients in modern pharmacology, moving beyond inert fillers to become active participants in drug stability and targeted release.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »